NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









FNCT Biotech

FNCT Biotech

Private
South KoreaHealthcare & Life Scienceshttps://fnctbiotech.com/

Last Round

Series B

Jun 16, 2026

Total Funding Raised

$18.15M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

FNCT Biotech is a biotechnology company that develops first-in-class antibody therapeutics for diseases with high unmet medical needs, particularly Idiopathic Pulmonary Fibrosis (IPF) and various cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

antibody therapeuticsIdiopathic Pulmonary FibrosisIPFmonoclonal antibodymAbsfirst-in-class therapeuticspreclinical biotechCSF3 targetbiotech out-licensinganti-fibrotic therapynovel drug targetdrug discoveryantibody discovery platformunmet medical needoncology therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

FNCT Biotech Comps

Public and private peers based on sector, stage, and business model.

FNCT Biotech comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

FNCT Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJun 16, 2026
Series AJan 20, 2025
SeedJul 1, 2022
View all Funding Rounds

Key People

Founding team and executive leadership

Lee Su-Jae

Chief Executive Officer

Executive Team

FNCT Biotech Investors

Notable investors and investment history

FNCT Biotech investors
InvestorRounds
DAYLI PartnersSeed
Premier PartnersSeries B
BSK InvestmentSeries B
IBK CapitalSeries B
NICE Investment PartnersSeries B
NH Nonghyup BankSeries B
Solidus InvestmentSeries B
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 16, 2026

    $14M round led by Premier Partners

  • Apr 3, 2026

    Monthly visitors increased 1157% MoM, reaching 2K.

View all signals

FNCT Biotech Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

FNCT Biotech Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about FNCT Biotech's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth Korea
Employee Range4
Year Founded2021
Last FundingJun 16, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.